Alpha Tau Medical Ltd

NASDAQ DRTS

Data sourced from

and

Daily

Download Data

Alpha Tau Medical Ltd Price to Book Ratio (P/B) on June 03, 2024: 2.32

Alpha Tau Medical Ltd Price to Book Ratio (P/B) is 2.32 on June 03, 2024, a 100.03% change year over year. The price to book ratio compares the market price per share of a company's stock to its book value per share. It is calculated by dividing the market capitalization by the shareholders' equity minus treasury stock, divided by the number of outstanding shares. This ratio provides insights into how the market values a company relative to its book value. A ratio above 1 indicates the market values the company more than its book value, suggesting positive market sentiment.

Alpha Tau Medical Ltd 52-week high Price to Book Ratio (P/B) is 3.27 on June 30, 2023, which is 40.73% above the current Price to Book Ratio (P/B).
Alpha Tau Medical Ltd 52-week low Price to Book Ratio (P/B) is -6,769.96 on June 06, 2023, which is -291,698.15% below the current Price to Book Ratio (P/B).
Alpha Tau Medical Ltd average Price to Book Ratio (P/B) for the last 52 weeks is -432.65.

NASDAQ: DRTS

Alpha Tau Medical Ltd

CEO	Mr. Uzi Sofer
IPO Date	March 8, 2021
Location	Israel
Headquarters	5 Kiryat Hamada Street, Jerusalem, Israel, 9777605
Employees	121
Sector	Healthcare
Industry	Biotechnology

Description

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. The company's Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; preclinical or pending clinical studies for brain and other cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. Alpha Tau Medical Ltd. was incorporated in 2015 and is headquartered in Jerusalem, Israel.

Key trends